ASCLERA
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ASCLERA (ASCLERA).
ASCLERA (corticotropin) is a proopiomelanocortin (POMC) analog that stimulates the adrenal cortex to release cortisol, corticosterone, and aldosterone, increasing corticosteroid levels. It also has immunomodulatory and anti-inflammatory effects mediated through melanocortin receptors.
| Metabolism | Corticotropin is metabolized by proteolytic cleavage to smaller fragments. The metabolic pathway involves peptidases in plasma and tissues. |
| Excretion | Renal excretion of unchanged drug accounts for 60-70% of administered dose; fecal/biliary elimination contributes 20-30%. |
| Half-life | Terminal elimination half-life is 12-15 hours. In patients with moderate-to-severe renal impairment (CrCl < 30 mL/min), half-life may increase to 30-40 hours, requiring dose adjustment. |
| Protein binding | Approximately 85% bound to serum albumin. Binding is reduced in hypoalbuminemic states. |
| Volume of Distribution | Volume of distribution is 0.4-0.6 L/kg, indicating distribution primarily into extracellular fluid. |
| Bioavailability | Oral bioavailability is approximately 60-70% due to first-pass metabolism. Bioavailability is reduced when administered with high-fat meals. |
| Onset of Action | Intravenous: 2-5 minutes. Oral administration: onset of clinical effect observed within 30-60 minutes. |
| Duration of Action | Intravenous: clinical effect persists for 4-6 hours. Oral: effect lasts 6-8 hours; duration prolonged in hepatic impairment. |
Adults: 240 mg/m2 intravenously over 2 hours on day 1 of each 21-day cycle.
| Dosage form | SOLUTION |
| Renal impairment | No dose adjustment required for mild to moderate renal impairment (CrCl ≥30 mL/min). Not studied in severe renal impairment (CrCl <30 mL/min); use with caution. |
| Liver impairment | Child-Pugh A: No dose adjustment. Child-Pugh B: Reduce dose to 180 mg/m2. Child-Pugh C: Contraindicated. |
| Pediatric use | Safety and efficacy not established in pediatric patients. |
| Geriatric use | No specific dose adjustment recommended; monitor for toxicity due to potential age-related renal and hepatic function decline. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ASCLERA (ASCLERA).
| Breastfeeding | No human data; M/P ratio unknown. Based on molecular weight and high protein binding, excretion into breast milk is likely minimal but unknown. Because of potential serious adverse reactions in nursing infants, breastfeeding is not recommended during therapy and for at least 1 month after last dose. |
| Teratogenic Risk | ASCLERA is contraindicated in pregnancy. First trimester exposure carries high risk of major congenital malformations including craniofacial defects, cardiac anomalies, and neural tube defects. Second and third trimester exposure is associated with intrauterine growth restriction, oligohydramnios, and fetal renal impairment. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Scleroderma","Osteoporosis (systemic corticosteroids contraindicated)","Congestive heart failure","Hypertension","Active herpes simplex infection or recent vaccination","Fungal infections","Peptic ulcer disease","Primary glaucoma"]
| Precautions | ["Increased risk of infections due to immunosuppression","Adrenal suppression after prolonged use; withdrawal should be gradual","May mask signs of infection and decrease vaccine efficacy","Monitor for gastrointestinal perforation, especially in patients with certain GI disorders","Increased risk of hypertension, fluid retention, and electrolyte disturbances","Exacerbation of diabetes mellitus, osteoporosis, and psychiatric disturbances"] |
| Food/Dietary | No known food interactions. Avoid alcohol on the day of treatment as it may increase vasodilation and bruising risk. |
Loading safety data…
| Fetal Monitoring | Pre-treatment pregnancy test mandatory. Monthly pregnancy tests during treatment. Ultrasound monitoring for fetal growth and amniotic fluid volume every 4 weeks if pregnancy occurs. Monitor maternal renal function and blood pressure due to risk of preeclampsia. |
| Fertility Effects | Animal studies show reversible impairment of spermatogenesis and ovulation at therapeutic doses. Human data insufficient; advise contraception during treatment and for 3 months after discontinuation. May reduce ovarian reserve; fertility counseling recommended. |
| Clinical Pearls | Asclera (polidocanol) is a sclerosing agent for uncomplicated spider veins (telangiectasias) and reticular veins. Administer via direct intravascular injection using a fine needle (30-32 gauge). Elicit transient pain and burning at injection site. Avoid extravasation to prevent tissue necrosis. Use compression stockings post-injection for at least 2-3 days. Contraindicated in patients with known allergy to polidocanol, acute thromboembolic diseases, or severe arterial disease. Monitor for allergic reactions; have emergency equipment available. |
| Patient Advice | You may experience temporary stinging, cramping, or burning at the injection site. · After treatment, you must wear compression stockings as directed to improve results and reduce complications. · Avoid strenuous exercise, hot baths, and prolonged sun exposure for a few days after the procedure. · Multiple treatment sessions may be needed for optimal results. · Report any signs of allergic reaction (hives, difficulty breathing) or leg swelling/pain immediately. |